Amalgamated Bank Trims Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Amalgamated Bank decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.0% in the fourth quarter, HoldingsChannel reports. The firm owned 67,983 shares of the company’s stock after selling 703 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were worth $8,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of NBIX. FCF Advisors LLC acquired a new stake in Neurocrine Biosciences during the 4th quarter valued at approximately $1,157,000. abrdn plc raised its holdings in shares of Neurocrine Biosciences by 2,503.0% during the fourth quarter. abrdn plc now owns 83,633 shares of the company’s stock worth $11,019,000 after purchasing an additional 80,420 shares during the last quarter. Redhawk Wealth Advisors Inc. purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth $1,245,000. HealthInvest Partners AB acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $1,662,000. Finally, Roman Butler Fullerton & Co. purchased a new stake in Neurocrine Biosciences in the fourth quarter valued at $1,256,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.6 %

NBIX stock opened at $140.71 on Friday. The business’s fifty day moving average price is $137.37 and its 200 day moving average price is $128.88. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37. The company has a market capitalization of $14.16 billion, a PE ratio of 38.76 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The business had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same quarter last year, the firm posted $0.88 earnings per share. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider David W. Boyer sold 456 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total transaction of $64,733.76. Following the completion of the transaction, the insider now directly owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now directly owns 29,512 shares in the company, valued at $3,909,454.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David W. Boyer sold 456 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the sale, the insider now owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The disclosure for this sale can be found here. Insiders sold 181,547 shares of company stock valued at $25,039,887 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NBIX shares. Guggenheim boosted their price objective on Neurocrine Biosciences from $164.00 to $170.00 and gave the company a “buy” rating in a report on Thursday. Barclays raised their price objective on shares of Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a research note on Thursday. BMO Capital Markets lifted their target price on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the company a “market perform” rating in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, March 20th. Six research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $147.88.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.